Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunosuppressant |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 1998 |
| gptkbp:ATCCode |
gptkb:L04AC02
|
| gptkbp:brand |
gptkb:Simulect
|
| gptkbp:CASNumber |
179045-86-4
|
| gptkbp:contraindication |
hypersensitivity to basiliximab
|
| gptkbp:developedBy |
gptkb:Novartis
|
| https://www.w3.org/2000/01/rdf-schema#label |
basiliximab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
IL-2 receptor antagonist
|
| gptkbp:molecularWeight |
144 kDa
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea hypertension peripheral edema |
| gptkbp:target |
gptkb:CD25
|
| gptkbp:UNII |
JX8W1O2F21
|
| gptkbp:usedFor |
prevention of organ rejection
|
| gptkbp:usedIn |
kidney transplantation
|
| gptkbp:bfsParent |
gptkb:Simulect
|
| gptkbp:bfsLayer |
5
|